Skip to main navigation

About Us

Our Company

Overview Management Team Board of Directors Scientific Advisory Board Partners & Collaborations

Contact

Our Pipeline

Pipeline

Overview Azenosertib ZN-d5 BCL-xL Degrader

Clinical Trials

Our Approach

Integrated Discovery Engine

Our advanced approach to efficiently identifying and developing novel oncology therapies.

Supporting Publications

Investors & Media

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Committee Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Careers

Working at Zentalis

Be part of a vibrant team committed to our common goal: to better the lives of patients impacted by cancer.

Job Opportunities

Investors & Media

Press Releases

Investor Relations Menu

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Board Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Contact

Katie Beach Oltsik
Evoke Canale
Katherine.Beach@evokegroup.com

Year

Sep 06, 2023

Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 01, 2023

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 09, 2023

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Aug 01, 2023

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 01, 2023

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

Jun 15, 2023

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

Jun 06, 2023

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

May 25, 2023

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

May 23, 2023

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

May 10, 2023

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Corporate Office

1359 Broadway
Suite 801
New York, NY 10018

Science Center

10275 Science Center Drive
Suite 200
San Diego, CA 92121

About Us

Our Company Management Team Board of Directors Scientific Advisory Board Partners & Collaborations Contact

Our Pipeline

Overview Azenosertib ZN-d5 BCL-xL Degrader Clinical Trials

Our Approach

Integrated Discovery Engine Supporting Publications

Investors & Media

News & Events Stock Information Financials & Filings Corporate Governance Investor Resources

Privacy Policy

Terms of Use

Expanded Access Policy

Site Map

Careers